Successful In-Vitro Validation of RIDE™ Platform

GERNA Biotech officially reports the successful in-vitro correction of severe genetic mutations utilizing its proprietary Cas-free RNA-guided innate repair enzyme technology.

Our latest milestone demonstrates the impeccable precision of the RIDE™ platform across multiple targets, including cystic fibrosis, Hunter syndrome, and critical oncogenic mutations like TP53 and JAK2.

This validates the platform's ability to selectively recruit innate human mismatch-repair machinery without the immunogenic or off-target risks typical of CRISPR/Cas systems. We anticipate advancing these candidates toward pre-clinical optimization shortly.